At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BLUE bluebird bio
Pre-Mkt 04-11 04:16:21 EDT
4.67
-0.18
-3.71%
| High4.85 | Low4.52 | Vol98.94K |
| Open4.85 | D1 Closing4.85 | Amplitude6.80% |
| Mkt Cap45.72M | Tradable Cap45.41M | Total Shares9.79M |
| T/O460.81K | T/O Rate1.02% | Tradable Shares9.72M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More
Zacks · 04-02
BRIEF-Xcellbio Granted Bluebird Bio Commercial License, Got Into Supply Agreement For Use Of Co's Proprietary Cell Manufacturing Technology, Avatar
Reuters · 04-02
Xcellbio: Granted bluebird bio Commercial License, Got Into Supply Agreement for Use of Co's Proprietary Cell Manufacturing Technology, Avatar
THOMSON REUTERS · 04-02
BUZZ-U.S. STOCKS ON THE MOVE-Veritex, Gaming and Leisure Properties, Apple
Reuters · 03-31
bluebird bio Is Maintained at Overweight by Barclays
Dow Jones · 03-31
Bluebird Bio Shares Rise After Non-Binding Offer From Ayrmid
Dow Jones · 03-31
BUZZ-U.S. STOCKS ON THE MOVE-Gene therapy cos, gold miners, chipmakers
Reuters · 03-31
BUZZ-Bluebird bio rises on non-binding bid for up to $110.5 million
Reuters · 03-31
Bluebird bio receives non-binding bid for up to $110.5 million
Reuters · 03-28
BUZZ-Bluebird Bio shares rally 11% in late trade on buyout offer
Reuters · 03-28
Bluebird Bio Reviewing Competing Buyout Offer From Ayrmid for Up to $110.5 Million
Dow Jones · 03-28
Bluebird Bio Gets Rival Buyout Proposal From Ayrmid; Shares Jump After Hours
MT Newswires Live · 03-28
BRIEF-Bluebird Bio Confirms Receipt Of An Unsolicited Non-Binding Proposal From Ayrmid
Reuters · 03-28
bluebird bio Inc Shares Gain Ground After the Bell Following Confirmation It Received Unsolicited Proposal, Last up 13% at Around $4.60
THOMSON REUTERS · 03-28
Bluebird Bio confirms receipt non-binding proposal from Ayrmid
TIPRANKS · 03-28
bluebird bio Inc - Board Reviewing Ayrmid Proposal With Advisors
THOMSON REUTERS · 03-28
bluebird bio Inc - Ayrmid Did Not Submit Any Proposal to Bluebird as Part of Its Review of Strategic Alternatives
THOMSON REUTERS · 03-28
bluebird bio Inc - Not Changed Its Recommendation in Support of Carlyle and SK Capital Partners Deal
THOMSON REUTERS · 03-28
bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal From Ayrmid
THOMSON REUTERS · 03-28
Press Release: bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid
Dow Jones · 03-28
Introduction
Company Name.
bluebird bio
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App